Improved specificity with 68 Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology

Published on Jan 1, 2019in European Journal of Nuclear Medicine and Molecular Imaging7.081
· DOI :10.1007/S00259-018-4160-7
Peter Donato4
Estimated H-index: 4
(Royal Brisbane and Women's Hospital),
Matthew J. Roberts20
Estimated H-index: 20
(UQ: University of Queensland)
+ 6 AuthorsJohn Yaxley22
Estimated H-index: 22
(UQ: University of Queensland)
Sources
Abstract
Purpose Positron emission tomography (PET) for prostate-specific membrane antigen (PSMA) represents a promising method for prostate cancer diagnosis and staging. Comparisons of PSMA-based tumour characterisation to multiparametric MRI (mpMRI) are limited, hence this study sought to compare the diagnostic accuracy of 68Ga-PSMA PET/CT to mpMRI against radical prostatectomy (RP) whole gland histopathology.
📖 Papers frequently viewed together
15 Citations
References47
Newest
#1Isabel Rauscher (TUM: Technische Universität München)H-Index: 20
#2Charlotte Düwel (TUM: Technische Universität München)H-Index: 4
Last. Matthias Eiber (TUM: Technische Universität München)H-Index: 22
view all 9 authors...
Abstract Recently, 68 Ga-labeled prostate-specific membrane antigen (PSMA)–ligand positron-emission tomography (PET) imaging has been shown to improve detection rates in recurrent prostate cancer (PC). However, published studies include only small patient numbers at low prostate-specific antigen (PSA) values. For this study, 272 consecutive patients with biochemical recurrence after radical prostatectomy and PSA value between 0.2 and 1ng/ml were included. The 68 Ga-PSMA-ligand PET/computed tomog...
89 CitationsSource
Introduction Prostate cancer (PC) most of the time presents with an indolent course. Thus, delays in treatment due to any causes might not affect long-term survival and may not affect cancer cure rates.
13 CitationsSource
#1Nadine Woythal (Charité)H-Index: 3
#2Ruza Arsenic (Charité)H-Index: 13
Last. Vikas Prasad (Charité)H-Index: 26
view all 9 authors...
: 68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA) PET/CT has a proven role in staging and restaging of prostate cancer (PCA). The aims of this study were to evaluate the association of intraprostatic 68Ga-PSMA PET/CT findings and PSMA expression in immunohistochemical staining and generate a cutoff value for differentiation between normal prostate (PN) and PCA. Methods: The data of 31 patients (mean age, 67.2 y) who underwent prostatectomy and preoperative PET were retrospectively an...
60 CitationsSource
#1Julia Corfield (University of Melbourne)H-Index: 3
#2Marlon Perera (Austin Hospital)H-Index: 21
Last. Nathan Lawrentschuk (University of Melbourne)H-Index: 58
view all 4 authors...
Purpose To systematically review currently available data on 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) used for the primary staging of high-risk prostate cancer.
89 CitationsSource
#1Marc Zanaty (UdeM: Université de Montréal)H-Index: 8
#2Mansour Alnazari (UdeM: Université de Montréal)H-Index: 4
Last. Kevin C. Zorn (UdeM: Université de Montréal)H-Index: 23
view all 15 authors...
Aim We sought to explore the impact of surgical wait time (SWT) to robot-assisted radical prostatectomy (RARP) on biochemical recurrence (BCR).
21 CitationsSource
#1Baris Turkbey (NIH: National Institutes of Health)H-Index: 76
#2Esther Mena (NIH: National Institutes of Health)H-Index: 23
Last. Peter L. Choyke (NIH: National Institutes of Health)H-Index: 140
view all 19 authors...
PurposeTo assess the ability of (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-18F-fluorobenzyl-L-cysteine) (18F-DCFBC), a prostate-specific membrane antigen–targeted PET agent, to detect localized prostate cancer lesions in correlation with multiparametric MRI (mpMRI) and histopathology.MethodsThis He
16 CitationsSource
#1Anna J. Yaxley (UQ: University of Queensland)H-Index: 3
#2John Yaxley (UQ: University of Queensland)H-Index: 22
Last. Morgan R. Pokorny (UQ: University of Queensland)H-Index: 1
view all 5 authors...
Objective: To compare the detection rates of prostate cancer (PCa) in men with Prostate Imaging–Reporting and Data System (PI-RADS) 3–5 abnormalities on 3-Tesla multiparametric (mp) magnetic resonance imaging (MRI) using in-bore MRI-guided biopsy compared with cognitively directed transperineal (cTP) biopsy and transrectal ultrasonography (cTRUS) biopsy. Methods: This was a retrospective single-centre study of consecutive men attending the private practice clinic of an experienced urologist perf...
31 CitationsSource
#1Sungmin Woo (SNU: Seoul National University)H-Index: 26
#2Chong Hyun Suh (UOU: University of Ulsan)H-Index: 33
Last. Seung Hyup Kim (SNU: Seoul National University)H-Index: 23
view all 5 authors...
Abstract Context In 2015, the updated Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) for the detection of prostate cancer (PCa) was established. Since then, several studies assessing the value of PI-RADSv2 have been published. Objective To review the diagnostic performance of PI-RADSv2 for the detection of PCa. Evidence acquisition MEDLINE and EMBASE databases were searched up to December 7, 2016. We included diagnostic accuracy studies that used PI-RADSv2 for PCa detection, us...
155 CitationsSource
#1Martijn G. Schouten (Radboud University Nijmegen)H-Index: 10
#2Marloes van der Leest (Radboud University Nijmegen)H-Index: 10
Last. Jurgen J. Fütterer (Radboud University Nijmegen)H-Index: 59
view all 7 authors...
Abstract Background Knowledge of significant prostate (sPCa) locations being missed with magnetic resonance (MR)- and transrectal ultrasound (TRUS)-guided biopsy (Bx) may help to improve these techniques. Objective To identify the location of sPCa lesions being missed with MR- and TRUS-Bx. Design, setting, and participants In a referral center, 223 consecutive Bx-naive men with elevated prostate specific antigen level and/or abnormal digital rectal examination were included. Histopathologically-...
80 CitationsSource
#1Ali Afshar-Oromieh (University Hospital Heidelberg)H-Index: 37
#2Tim Holland-Letz (DKFZ: German Cancer Research Center)H-Index: 27
Last. Uwe Haberkorn (University Hospital Heidelberg)H-Index: 85
view all 16 authors...
Purpose Since the clinical introduction of 68Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort.
321 CitationsSource
Cited By32
Newest
#1Massimo Lazzeri (Humanitas University)H-Index: 64
#2Arturo Chiti (Humanitas University)H-Index: 54
Source
#1A. Tariq (Royal Brisbane and Women's Hospital)
#2Amy E. McCart Reed (UQ: University of Queensland)H-Index: 15
Last. Matthew J. Roberts (UQ: University of Queensland)H-Index: 20
view all 9 authors...
Abstract null null Context null Staging, restaging, and surveillance of urothelial carcinoma (UC) is challenging due to suboptimal accuracy of standard of care imaging modalities. Prostate-specific membrane antigen (PSMA) imaging may serve to improve characterisation of UC. null null null Objective null To appraise available literature regarding cellular, imaging, and prognostic implications of PSMA for UC. null null null Evidence acquisition null A systematic review was performed considering al...
Source
#1Stephen McGeorge (UQ: University of Queensland)H-Index: 1
#2Michael Kwok (UQ: University of Queensland)
Last. Matthew J. RobertsH-Index: 20
view all 0 authors...
PSMA PET is more accurate than conventional imaging (CT/bone scan) for staging of intermediate- or high-risk prostate cancer (PCa), but 5–10% of primary tumours have low PSMA ligand uptake. FDG PET has been used to further define disease extent in end-stage castrate-resistant PCa and may be beneficial earlier in the disease course for more accurate staging. The objective of this study was to review the available evidence for patients undergoing both FDG and PSMA PET for PCa staging at initial di...
Source
#1Farshad Moradi (Stanford University)H-Index: 20
#2Andrea FarolfiH-Index: 8
Last. Andrei Iagaru (Stanford University)H-Index: 37
view all 4 authors...
Abstract null null The role of molecular imaging in initial evaluation of men with presumed or established diagnosis of prostate cancer and work up of biochemical recurrence and metastatic disease is rapidly evolving due to superior diagnostic performance compared to anatomic imaging. However, variable tumor biology and expression of transmembrane proteins or metabolic alterations poses a challenge. We review the evidence and controversies with emphasis on emerging PET radiopharmaceuticals and e...
Source
#1François LuciaH-Index: 7
#2O. MirandaH-Index: 4
Last. Ulrike SchickH-Index: 23
view all 6 authors...
Functional imaging allows the evaluation of numerous biological properties that could be considered at all steps of the therapeutic management of patients treated with brachytherapy. Indeed, it enables better initial staging of the disease, and some parameters may also be used as predictive biomarkers for treatment response, allowing better selection of patients eligible for brachytherapy. It may also improve the definition of target volumes with the aim of dose escalations by dose-painting. Fin...
Source
#1Bastiaan M. Privé (Radboud University Nijmegen)H-Index: 2
#2Bas Israël (Radboud University Nijmegen)H-Index: 5
Last. James Nagarajah (Radboud University Nijmegen)H-Index: 20
view all 15 authors...
BACKGROUND PSMA-PET is a novel imaging modality for the staging of prostate cancer (PCa). While there are several PSMA ligands available, F-18-PSMA-1007 is particularly of interest as it is not renally excreted and therefore does not impair the imaging of the pelvic area. Hence, this study aimed to investigate the F-18-PSMA-1007-PET for the primary staging of PCa and compared it to multi-parametric (mp) MRI and histopathology. METHODS A retrospective study was performed of men with intermediate ...
4 CitationsSource
#1Ur Metser (Women's College Hospital)H-Index: 35
#2Claudia Ortega (Women's College Hospital)H-Index: 1
Last. Sangeet Ghai (Women's College Hospital)H-Index: 22
view all 12 authors...
PURPOSE To assess whether 18F-DCFPyL PET/multiparametric (mp)MR contributes to the diagnosis of clinically significant (cs) prostate cancer (PCa) compared to mpMR in patients with suspicion of PCa, or patients being considered for focal ablative therapies (FT). PATIENTS AND METHODS This ethics review board-approved, prospective study included 55 men with suspicion of PCa and negative systematic biopsies or clinically discordant low-risk PCa (n = 21) or those being considered for FT (n = 34) who ...
1 CitationsSource
#1Eivor Hernes (Oslo University Hospital)H-Index: 13
#2Mona-Elisabeth Revheim (Oslo University Hospital)H-Index: 12
Last. Therese Seierstad (Oslo University Hospital)H-Index: 20
view all 7 authors...
Prostate-specific membrane antigen PET is a promising diagnostic tool in prostate cancer. The gold standard for the detection of prostate tumor and lymph node metastases is histopathology. The aim of the present review was to investigate accuracy measures of 68Ga/18F-labeled prostate-specific membrane antigen PET tracers in primary and recurrent prostate cancer with systematic sector-based histopathology as the reference standard. A systematic literature search was performed and 34 studies were ...
1 CitationsSource
#1Matthew J. RobertsH-Index: 20
#2Andrew Morton (UQ: University of Queensland)H-Index: 5
Last. John Yaxley (UQ: University of Queensland)H-Index: 22
view all 13 authors...
PURPOSE Prostate-specific membrane antigen (PSMA) positron emission tomography (PSMA-PET) improves prostate cancer staging. Intraprostatic PSMA intensity may predict clinically relevant oncological outcomes. The aim of this study was to investigate the relationship between intraprostatic PSMA intensity and adverse pathology outcomes, including biochemical progression-free survival (PFS) after radical prostatectomy. METHODS This is a cohort study of 71 patients with MRI-guided, biopsy-proven pros...
13 CitationsSource
#2John B. AndersonH-Index: 1
Last. Stefano Fanti (UNIBO: University of Bologna)H-Index: 83
view all 4 authors...
INTRODUCTION Prostate specific membrane antigen (PSMA) positron emission tomography (PET) with computed tomography (CT) is a promising molecular imaging technique for prostate cancer (PCa). Although not yet included in international guidelines, PSMA PET/CT is commonly used in clinical practice to stage patients with newly diagnosed PCa. This review focuses on the most up-to-date literature on staging high risk prostate cancer with PSMA PET/CT. METHODS An online based literature research encompas...
1 CitationsSource